COMMUNIQUÉS West-GlobeNewswire
-
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026
03/08/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2026
03/08/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
03/08/2026 -
The Ferrari Foundation Advances Fifth Annual Adam Ferrari Health Science Scholarship to Finalist Review
03/08/2026 -
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
03/08/2026 -
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
03/08/2026 -
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
03/08/2026 -
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
03/08/2026 -
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
03/08/2026 -
Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
03/08/2026 -
Neuronetics and Jorey Chernett Announce Shared Vision
03/08/2026 -
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
03/08/2026 -
electroCore to Participate in Upcoming Investor Conferences
03/08/2026 -
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
03/08/2026 -
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
03/08/2026 -
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
03/08/2026 -
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
03/08/2026 -
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
03/08/2026 -
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
03/08/2026
Pages